United States Drug Patent RE43879: Claim Scope, Validity, Exclusivity and Milnacipran Patent Landscape
U.S. Patent RE43879 covers methods of treating serotonin-norepinephrine reuptake inhibitor-responsive disorders with milnacipran hydrochloride mixtures enriched in the dextrogyral enantiomer, principally to reduce cardiovascular, hepatic, renal, or other toxicity relative to racemic milnacipran. The patent does not broadly claim all milnacipran products. Its practical scope depends on four limitations: enantiomeric enrichment, treatment of a qualifying disorder, risk reduction compared with racemic milnacipran, and, for certain claims, combination therapy or sustained-release dosing.
The patent is a method-of-use reissue patent. It does not create composition-of-matter protection over racemic milnacipran hydrochloride, and it does not automatically block generic racemic milnacipran products. Its strongest potential relevance is to an enriched-dextrogyral product, a sustained-release product using that mixture, or a labeled treatment protocol directed to patients at heightened cardiovascular, hepatic, or renal risk.
What patents protect the dextrogyral milnacipran treatment method?
RE43879 protects treatment methods using a mixture of milnacipran enantiomers that is substantially enriched in the dextrogyral enantiomer. The claims compare that enriched mixture with racemic milnacipran and require that administration limit specified risks.
The claim architecture is:
| Claim group |
Subject matter |
Principal limitation |
| Claims 1-16 |
Treatment with enriched dextrogyral milnacipran |
Reduced cardiovascular or organ/tissue toxicity relative to racemate |
| Claims 5-7 |
Enantiomeric enrichment |
Greater than 95:5, greater than 99:1, and a separately stated ratio in claim 7 |
| Claims 8-16 |
Disease and patient populations |
Broad psychiatric, neurologic, pain, cardiovascular, urinary, addiction, pediatric, elderly, hepatic, renal, and cardiac-risk populations |
| Claims 17-19 |
Depression combination therapy |
Enriched milnacipran plus a psychotropic, including antidepressants or antimuscarinic agents |
| Claims 20-21 |
Combination therapy with organ- or cell-toxic agents |
Enriched milnacipran plus agents inducing hepatic or renal toxicity |
| Claims 22 |
Combination therapy with cardiovascular-risk agents |
Enriched milnacipran plus agents inducing cardiovascular side effects |
| Claims 23-25 |
Sustained-release treatment for depression |
Enriched mixture, sustained-release dosage form, and weight-based dose range |
The independent claims are method claims rather than product claims. A product manufacturer would generally face infringement risk only if its product and labeling support the claimed treatment method, particularly the dextrogyral enrichment and risk-limitation limitations.
How broad are claims 1 through 16?
Claims 1 through 16 are broad in disease coverage but narrow in pharmacologic and clinical requirements.
Claim 1 requires all of the following:
- A patient with a condition treatable by dual serotonin and norepinephrine reuptake inhibition.
- Administration of a mixture of milnacipran hydrochloride enantiomers.
- Substantial purity in the dextrogyral enantiomer.
- Treatment efficacy.
- Limitation of cardiovascular, organ, or tissue toxicity relative to racemic milnacipran.
The phrase "relative to administration of racemic milnacipran hydrochloride" is central. It is a comparative, functional limitation. A claimant would need to establish that the accused administration produces the required risk-limiting effect, either through clinical evidence, pharmacology, or an appropriate inherency theory.
Claim 2 narrows the cardiovascular limitation to increased blood pressure or heart rate. Claim 3 focuses on diastolic blood pressure. Claim 4 identifies cardiac, hepatic, and renal toxicity.
Claims 5 and 6 create quantitative enrichment thresholds:
- Greater than 95:5 dextrogyral-to-levogyral ratio.
- Greater than 99:1 dextrogyral-to-levogyral ratio.
Claim 7, as supplied, states "greater than 99:5:0.5" for a two-enantiomer ratio. That language is internally irregular because it expresses three numerical components while identifying only dextrogyral and levogyral enantiomers. Its enforceability would depend on the issued patent text, prosecution history, and any correction or construction adopted by a court.
What diseases and patient populations are covered?
Claim 8 lists an unusually wide range of indications. It reaches depression, bipolar disease, schizophrenia, generalized anxiety, panic attacks, phobias, obsessive-compulsive disorders, post-traumatic stress disorder, attention disorders, eating disorders, obesity, migraine, pain, irritable bowel syndrome, cardiovascular disease, neurodegenerative disease, urinary incontinence, and drug addiction.
Claims 9 through 14 narrow selected indications, including:
- Resistant, psychotic, seasonal, elderly, and treatment-induced depression.
- Agoraphobia.
- Chronic pain.
- Anxiety-depressive syndromes associated with myocardial infarction or hypertension.
- Stress urinary incontinence and enuresis.
- Tobacco, nicotine, alcohol, narcotic, drug, and analgesic addiction.
Claim 15 expands the protected patient population to patients who may be more vulnerable to adverse effects, including children, elderly patients, patients with hepatic or renal insufficiency, patients receiving hepatotoxic or nephrotoxic therapy, patients receiving cardiac treatment, and patients with cardiovascular disease.
Claim 16 identifies myocardial infarction, rhythm disorders, blood-pressure disorders, and heart disease.
The disease list does not by itself establish infringement. The accused treatment must still satisfy the enriched-enantiomer and comparative toxicity limitations.
What formulations are protected by RE43879?
Claims 23 through 25 provide the clearest formulation-specific protection. They require:
- A sustained-release pharmaceutical form.
- Treatment of depression.
- An enriched dextrogyral milnacipran mixture.
- A daily dose of 0.01 to 10 mg/kg in claim 23.
- A daily dose of 0.05 to 5 mg/kg in claim 24.
- A daily dose of 0.1 to 1 mg/kg in claim 25.
The claims do not appear to require a particular polymer, matrix, coating, capsule, tablet, release profile, particle size, or manufacturing process. The formulation limitation is therefore functional and dosage-based rather than technology-specific.
A sustained-release racemic milnacipran product would not necessarily infringe claims 23 through 25 because the claims require substantial enrichment in the dextrogyral enantiomer. Conversely, an enriched product in immediate-release form would face less exposure to these claims, although claims 1 through 22 could remain relevant.
How does RE43879 compare with racemic milnacipran patents?
| Issue |
RE43879 |
Racemic milnacipran patents |
| Protected subject matter |
Treatment method using enantiomer-enriched mixture |
Drug substance, formulation, treatment method, or indication |
| Active ingredient |
Dextrogyral-enriched milnacipran hydrochloride mixture |
Racemic milnacipran hydrochloride |
| Product coverage |
Indirect and limited |
Potentially direct, depending on claim type |
| Toxicity limitation |
Expressly required |
Usually not required unless included in the claim |
| Depression |
Covered broadly and specifically |
Depends on the individual patent |
| Fibromyalgia |
Not expressly identified in the supplied claims, although pain and related disorders are included |
Central to the U.S. commercial product, Savella |
| Sustained release |
Claims 23-25 |
May be covered by separate formulation patents |
| Generic racemic entry |
Limited direct exposure |
Primarily controlled by racemic product patents and regulatory exclusivity |
Milnacipran was approved in the United States as Savella for fibromyalgia, not as a general antidepressant. The FDA approved Savella in January 2009 under NDA 022256. The product contains milnacipran hydrochloride and is administered as a racemic product under the approved labeling. [1]
RE43879 therefore occupies a different position from patents covering Savella's racemic active ingredient or its fibromyalgia indication. It is an enantiomer-selective follow-on patent directed to toxicity reduction and selected treatment protocols.
What is the Orange Book status of RE43879?
Orange Book relevance depends on whether the patent is listed against an approved drug product and whether the approved product practices the patent claims. The FDA Orange Book lists patents and exclusivity associated with approved products, not every potentially relevant pharmaceutical patent. [2]
RE43879 presents a listing mismatch risk because its claims require a dextrogyral-enriched mixture, while the U.S. Savella product is identified as milnacipran hydrochloride and was approved as a racemic product. A patent directed to an enriched enantiomer may not be coextensive with the approved racemic product.
For a generic applicant seeking approval of racemic milnacipran, the principal regulatory questions are:
- Whether RE43879 is listed for the relevant reference product.
- Whether the proposed product label includes a use covered by the patent.
- Whether the applicant can use a section viii statement to carve out patented uses.
- Whether the patent term has expired.
- Whether other listed Savella patents create a separate Paragraph IV risk.
Under the Hatch-Waxman framework, a Paragraph IV certification alleges that a listed patent is invalid, unenforceable, or not infringed. A listed method-of-use patent can also be addressed through a proposed labeling carve-out where the approved indication permits one. [3]
When does RE43879 lose exclusivity?
A reissue patent cannot extend the enforceable term beyond the term of the original patent. Under 35 U.S.C. § 251, reissue corrects an issued patent but does not provide a new twenty-year term. Patent term is generally measured from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory adjustments. [4]
The practical exclusivity assessment for RE43879 requires examination of:
- The original patent from which RE43879 issued.
- The earliest effective U.S. or foreign priority date.
- Patent-term adjustment.
- Any patent-term extension.
- Any terminal disclaimer.
- Maintenance-fee status.
- Certificate-of-correction history.
- Reissue prosecution history.
Because the claims concern an enantiomer-enriched treatment rather than the approved racemic product, expiration of RE43879 would remove a potential method-of-use barrier but would not determine the status of separate racemic milnacipran patents.
As of 2026, a patent with an ordinary 20-year term based on an early-2000s priority or filing date would generally have reached the end of its statutory term unless a specific adjustment or extension applies. The controlling date must be taken from the USPTO patent record for the original patent and not from the 2013 reissue grant date. [5]
Which companies are challenging milnacipran exclusivity?
The relevant competitive field includes:
- The Savella reference-product sponsor and its successors.
- Generic manufacturers seeking approval of racemic milnacipran hydrochloride.
- Potential developers of single-enantiomer or enriched-enantiomer milnacipran.
- Companies developing extended-release or abuse-resistant formulations.
- Manufacturers seeking non-U.S. approval where U.S. Orange Book patents have no direct effect.
Generic competition to racemic milnacipran does not necessarily establish a commercial challenge to RE43879. A generic product can avoid the patent by using racemic material, omitting patented indications, using immediate release, or relying on expiration of the patent term.
A company developing dextrogyral-enriched milnacipran faces a different risk profile. It may need to address:
- Patent validity under anticipation and obviousness standards.
- Written-description support for the enantiomeric ratios.
- Enablement of the claimed toxicity reduction across the broad disease list.
- Definiteness of "substantially pure" and "limits the risks."
- Inherency of cardiovascular or organ-safety benefits.
- Whether the proposed label induces performance of the claimed method.
How strong is the patent estate for RE43879?
The estate is strongest against a product that satisfies all four of these conditions:
- It contains a dextrogyral-enriched milnacipran mixture.
- Its enrichment exceeds one of the stated thresholds.
- Its label identifies treatment of depression or another listed disorder.
- Its labeling or clinical use targets patients with cardiovascular, hepatic, renal, or toxicity-related risk.
The estate is weaker against:
- Racemic milnacipran.
- A product with no dextrogyral enrichment.
- A product with enrichment below the asserted threshold.
- A product marketed for an indication outside the label.
- A product with no sustained-release formulation where claims 23-25 are asserted.
- A product whose label omits the toxicity-reduction theory and does not encourage the claimed patient selection.
Potential validity pressure points include the breadth of the disease list, the comparative toxicity limitation, the clinical support for reduced cardiovascular risk, and the numerical and linguistic irregularity of claim 7. The claims also combine a broad functional treatment theory with a very large set of patient populations. That combination can create written-description and enablement issues if the specification does not provide representative data or a credible technical rationale across the full scope.
What generic launch risks exist?
Racemic immediate-release launch
This is the lowest direct RE43879 risk if the product does not use the claimed enriched mixture and its labeling does not induce use of a patented method. The principal barriers would be separate Orange Book patents, regulatory exclusivity, and ordinary product liability considerations.
Racemic sustained-release launch
The sustained-release format may implicate separate formulation patents. RE43879 claims 23 through 25 remain less relevant if the product is racemic, but a broader patent covering release technology could apply.
Enriched-dextrogyral launch
This is the highest RE43879 risk. The developer would need to address composition identity, enantiomeric ratio, clinical labeling, comparative safety evidence, and method-of-use infringement.
Skinny-label launch
A section viii carve-out may reduce risk where the patented indication can be omitted and the remaining label does not encourage the patented use. It does not eliminate liability if the marketed product, promotional materials, or label otherwise induce performance of the claims.
Does RE43879 create biosimilar risk?
No conventional biosimilar pathway applies. Milnacipran hydrochloride is a small-molecule active pharmaceutical ingredient, not a biologic subject to the Biologics Price Competition and Innovation Act. [6]
The relevant competitors are ANDA applicants, 505(b)(2) applicants, and independent new drug applicants. A 505(b)(2) applicant developing an enriched-enantiomer or modified-release product could face both patent litigation and clinical bridging requirements distinct from a conventional racemic ANDA.
What litigation and settlement issues matter?
Any litigation assessment should distinguish:
- Infringement of the original patent.
- Infringement of the reissue claims.
- Validity of the reissue claims.
- Patent-term status.
- Orange Book listing and Paragraph IV jurisdiction.
- Label-induced infringement.
- Settlement restrictions under the Hatch-Waxman framework.
A settlement involving racemic milnacipran would not necessarily resolve rights to enriched dextrogyral milnacipran. Conversely, a settlement concerning an enriched-enantiomer product could have limited relevance to generic racemic entry.
The decisive documents are the original patent, the reissue file history, any terminal disclaimer, FDA listing records, ANDA litigation complaints, and any consent judgment or settlement filed with the court. Public litigation databases and FDA records should be read together because patent expiration, listing, and litigation status are separate issues. [2, 5, 7]
Key Takeaways
- RE43879 is a method-of-use patent directed to dextrogyral-enriched milnacipran hydrochloride.
- It does not broadly cover racemic milnacipran or every Savella product.
- The comparative toxicity limitation is central to infringement and validity.
- Claims 5 and 6 require more than 95:5 or more than 99:1 dextrogyral-to-levogyral enrichment.
- Claims 17-22 cover combination therapy with psychotropic, organ-toxic, cell-toxic, or cardiovascular-risk agents.
- Claims 23-25 add sustained-release and weight-based dosing limitations for depression.
- The patent has no biosimilar pathway because milnacipran is a small molecule.
- Generic racemic entry is more likely to be controlled by separate product, formulation, indication, or Orange Book patents.
- An enriched-dextrogyral product would face substantially greater exposure than a conventional racemic generic.
- The enforceable term must be determined from the original patent term, not the reissue grant date.
- Claim 7 presents a potential construction issue because the stated ratio is expressed as a three-part ratio for two enantiomers.
FAQs About U.S. Patent RE43879 and Milnacipran Exclusivity
Does RE43879 cover Savella?
It does not automatically cover Savella. The claims require a mixture substantially enriched in the dextrogyral enantiomer, while Savella is the approved racemic milnacipran product.
Can a generic milnacipran applicant avoid RE43879?
A racemic product may avoid the claims if it does not satisfy the enriched-enantiomer limitation and does not induce a patented method of treatment. Other listed patents may create separate entry barriers.
Is dextrogyral milnacipran the same as racemic milnacipran?
No. Racemic milnacipran contains both enantiomers. The claimed product is a mixture substantially enriched in the dextrogyral enantiomer.
Do claims 23 through 25 cover every extended-release milnacipran product?
No. They require an enriched dextrogyral mixture, treatment of depression, sustained release, and the specified dose ranges. A racemic extended-release product would not satisfy those limitations solely because it is extended release.
What is the main invalidity risk for RE43879?
The principal issues are likely to be support for the broad comparative toxicity limitation, enablement across the extensive disease and patient lists, definiteness of functional terms such as "substantially pure" and "limits the risks," and the construction of claim 7.
References
-
U.S. Food and Drug Administration. (2009). Savella (milnacipran hydrochloride) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
21 U.S.C. § 355(j) (2024).
-
35 U.S.C. §§ 154, 251, 271, 282 (2024).
-
U.S. Patent and Trademark Office. (2025). Patent Center and patent term adjustment records. USPTO.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable products. FDA.
-
U.S. Courts. (2025). PACER case locator and federal patent litigation records. Administrative Office of the United States Courts.
